Plus Therapeutics Introduces REYOBIQ, FDA-Accepted Proprietary Name for Lead Drug Candidate (GlobeNewswire) - Mar 20, 2025 - "Plus Therapeutics, Inc...today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company's new proprietary name, REYOBIQ, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ must be submitted once the marketing application (NDA) is submitted. All communications regarding the USAN-adopted and INN-recommended rhenium Re186 obisbemeda generic name will now utilize the proprietary name REYOBIQ."
FDA event • CNS Tumor
|